Is Akoya Biosciences Stock a Good Investment?
Akoya Biosciences Investment Advice | AKYA |
- Examine Akoya Biosciences' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Akoya Biosciences' leadership team and their track record. Good management can help Akoya Biosciences navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact Akoya Biosciences' business and its evolving consumer preferences.
- Compare Akoya Biosciences' performance and market position to its competitors. Analyze how Akoya Biosciences is positioned in terms of product offerings, innovation, and market share.
- Check if Akoya Biosciences pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Akoya Biosciences' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Akoya Biosciences stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Akoya Biosciences is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Akoya Biosciences Stock
Researching Akoya Biosciences' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 70.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 1.16. Akoya Biosciences had not issued any dividends in recent years.
To determine if Akoya Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Akoya Biosciences' research are outlined below:
| Akoya Biosciences generated a negative expected return over the last 90 days | |
| Akoya Biosciences has high historical volatility and very poor performance | |
| Akoya Biosciences has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 96.63 M. Net Loss for the year was (63.32 M) with profit before overhead, payroll, taxes, and interest of 43.39 M. | |
| Akoya Biosciences currently holds about 87.61 M in cash with (50.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.31, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 70.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from investing.com: Akoya Biosciences stock target cut, rating held on recent earnings report |
Akoya Biosciences Quarterly Good Will |
|
Akoya Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Akoya Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Akoya Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Akoya Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Akoya Biosciences' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-14 | 2024-09-30 | -0.2 | -0.1786 | 0.0214 | 10 | ||
2021-08-10 | 2021-06-30 | -0.23 | -0.2 | 0.03 | 13 | ||
2024-03-04 | 2023-12-31 | -0.27 | -0.22 | 0.05 | 18 | ||
2022-05-05 | 2022-03-31 | -0.39 | -0.44 | -0.05 | 12 | ||
2021-11-08 | 2021-09-30 | -0.26 | -0.31 | -0.05 | 19 | ||
2023-03-06 | 2022-12-31 | -0.43 | -0.5 | -0.07 | 16 | ||
2022-08-08 | 2022-06-30 | -0.37 | -0.47 | -0.1 | 27 | ||
2023-11-08 | 2023-09-30 | -0.37 | -0.26 | 0.11 | 29 |
Know Akoya Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Akoya Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Akoya Biosciences backward and forwards among themselves. Akoya Biosciences' institutional investor refers to the entity that pools money to purchase Akoya Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 216.4 K | Northern Trust Corp | 2024-09-30 | 210.5 K | Osterweis Capital Management Inc | 2024-09-30 | 126.1 K | Bridgeway Capital Management, Llc | 2024-09-30 | 105.6 K | Bank Of New York Mellon Corp | 2024-06-30 | 67.5 K | Squarepoint Ops Llc | 2024-06-30 | 65.9 K | Charles Schwab Investment Management Inc | 2024-09-30 | 63 K | Citadel Advisors Llc | 2024-09-30 | 51.8 K | Zeliff Wallace Jackson Invst Counsel Inc | 2024-09-30 | 45.3 K | Blue Water Life Science Advisors, Llc | 2024-09-30 | 4.7 M | Blackrock Inc | 2024-06-30 | 1.5 M |
Akoya Biosciences' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 106.07 M.Market Cap |
|
Akoya Biosciences' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.44) | (0.46) | |
| Return On Capital Employed | (0.40) | (0.42) | |
| Return On Assets | (0.35) | (0.37) | |
| Return On Equity | (1.18) | (1.24) |
Determining Akoya Biosciences' profitability involves analyzing its financial statements and using various financial metrics to determine if Akoya Biosciences is a good buy. For example, gross profit margin measures Akoya Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Akoya Biosciences' profitability and make more informed investment decisions.
Akoya Biosciences' Earnings Breakdown by Geography
Please note, the presentation of Akoya Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Akoya Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Akoya Biosciences' management manipulating its earnings.
Evaluate Akoya Biosciences' management efficiency
Akoya Biosciences has return on total asset (ROA) of (0.1809) % which means that it has lost $0.1809 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.282) %, meaning that it created substantial loss on money invested by shareholders. Akoya Biosciences' management efficiency ratios could be used to measure how well Akoya Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of November 29, 2024, Return On Tangible Assets is expected to decline to -0.46. In addition to that, Return On Capital Employed is expected to decline to -0.42. At present, Akoya Biosciences' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 59.4 M, whereas Total Assets are forecasted to decline to about 157.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.21 | 0.91 | |
| Tangible Book Value Per Share | 0.41 | 0.43 | |
| Enterprise Value Over EBITDA | (4.81) | (5.05) | |
| Price Book Value Ratio | 4.03 | 4.85 | |
| Enterprise Value Multiple | (4.81) | (5.05) | |
| Price Fair Value | 4.03 | 4.85 | |
| Enterprise Value | 219.4 M | 394 M |
The strategic vision of Akoya Biosciences management plays a critical role in its financial performance. By evaluating this vision, we provide insights into the stock's growth potential.
Beta 1.346 |
Basic technical analysis of Akoya Stock
As of the 29th of November, Akoya Biosciences shows the Mean Deviation of 3.85, standard deviation of 5.65, and Risk Adjusted Performance of 2.0E-4. Akoya Biosciences technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Akoya Biosciences' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Akoya Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Akoya Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Akoya Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Akoya Biosciences' Outstanding Corporate Bonds
Akoya Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Akoya Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Akoya bonds can be classified according to their maturity, which is the date when Akoya Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Understand Akoya Biosciences' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Akoya Biosciences' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 2.0E-4 | |||
| Market Risk Adjusted Performance | (0.02) | |||
| Mean Deviation | 3.85 | |||
| Coefficient Of Variation | (9,066) | |||
| Standard Deviation | 5.65 | |||
| Variance | 31.94 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.34) | |||
| Total Risk Alpha | (0.92) | |||
| Treynor Ratio | (0.03) | |||
| Maximum Drawdown | 40.94 | |||
| Value At Risk | (4.96) | |||
| Potential Upside | 8.59 | |||
| Skewness | (0.26) | |||
| Kurtosis | 5.14 |
| Risk Adjusted Performance | 2.0E-4 | |||
| Market Risk Adjusted Performance | (0.02) | |||
| Mean Deviation | 3.85 | |||
| Coefficient Of Variation | (9,066) | |||
| Standard Deviation | 5.65 | |||
| Variance | 31.94 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.34) | |||
| Total Risk Alpha | (0.92) | |||
| Treynor Ratio | (0.03) | |||
| Maximum Drawdown | 40.94 | |||
| Value At Risk | (4.96) | |||
| Potential Upside | 8.59 | |||
| Skewness | (0.26) | |||
| Kurtosis | 5.14 |
Consider Akoya Biosciences' intraday indicators
Akoya Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Akoya Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Akoya Biosciences Corporate Filings
F4 | 21st of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 14th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 4th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
F3 | 3rd of September 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Akoya Stock media impact
Far too much social signal, news, headlines, and media speculation about Akoya Biosciences that are available to investors today. That information is available publicly through Akoya media outlets and privately through word of mouth or via Akoya internal channels. However, regardless of the origin, that massive amount of Akoya data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Akoya Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Akoya Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Akoya Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Akoya Biosciences alpha.
Akoya Biosciences Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Akoya Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Akoya Biosciences Corporate Management
| Clifford Hoyt | VP Affairs | Profile | |
| Marilee MBA | Chief Officer | Profile | |
| Jennifer Kamocsay | General Counsel | Profile | |
| Nikolay Samusik | CoFounder | Profile | |
| Priyam Shah | Senior Strategy | Profile |
Already Invested in Akoya Biosciences?
The danger of trading Akoya Biosciences is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Akoya Biosciences is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Akoya Biosciences. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Akoya Biosciences is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Akoya Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Akoya Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Akoya Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Akoya Biosciences Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akoya Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For information on how to trade Akoya Stock refer to our How to Trade Akoya Stock guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akoya Biosciences. If investors know Akoya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akoya Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.16) | Revenue Per Share 1.889 | Quarterly Revenue Growth (0.01) | Return On Assets (0.18) | Return On Equity (1.28) |
The market value of Akoya Biosciences is measured differently than its book value, which is the value of Akoya that is recorded on the company's balance sheet. Investors also form their own opinion of Akoya Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Akoya Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akoya Biosciences' market value can be influenced by many factors that don't directly affect Akoya Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Akoya Biosciences' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Akoya Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akoya Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.